Experiences with Amodiaquin (Camoquin A New Synthetic Antimalarial

View More View Less

At the beginning of 1948 a supply of a new synthetic antimalarial became available. This drug, amodiaquin (Camoquin Hydrochloride) is 4(3′-diethylamino-methyl-4′-hydroxyanilino)-7-chloroquinoline dihydrochloride dihydrate. It is a light yellow, crystalline powder which forms a 5 per cent solution in water at room temperature. It was first reported at the meeting of the American Chemical Society by Burckhalter et al. (1) in 1946. Its toxicity and tolerance have been determined by the parent laboratory, and it has been studied clinically (2, 3, 4, 5, 6, 7, 8, 9, 10) in numerous countries.

La Paz, Bolivia, where this study was conducted offers a fortunate combination of circumstances for a therapeutic evaluation of an antimalarial. Due to the cool climate and the altitude no vectors of the disease exist, thus there is no danger of reinfections contaminating the resulting follow-up observation. Second, the altitude increases the tendency of a dormant case of malaria to relapse.

Author Notes

Professor of Tropical Pathology, University of San Andrés, La Paz, Bolivia.